Beijing Hope Pharmaceutical Co., Ltd. is a high-tech pharmaceutical company based in China and facing the world. The main business is R&D, production and sales of APIs and APIs, import and export trade, R&D of new pharmaceutical preparations and new drug registration. We have an R&D center in Beijing, a pharmaceutical intermediate production base in Hebei and Zhejiang, and a GMP-certified API production base in Shandong.
*The following content is generated by AI and is for reference only.
Sugammadex sodium is a revolutionary cyclodextrin-based pharmaceutical agent designed for the rapid reversal of neuromuscular blockade induced by steroidal muscle relaxants, specifically rocuronium and vecuronium. Its unique molecular architecture consists of a modified gamma-cyclodextrin ring with negatively charged carboxylate groups that allow it to act as a selective "molecular cage." The chemical formula for Sugammadex sodium is approximately C48H60Na12O36, reflecting its complex structure containing twelve sodium ions associated with the anionic form of the molecule. While a single definitive CAS number is often cited as 57994-05-5 for the specific sodium salt formulation, variations may exist depending on the degree of substitution and hydration state in different manufacturing batches.
The primary clinical utility of Sugammadex lies in its ability to encapsulate rocuronium or vecuronium molecules within its hydrophobic cavity through non-covalent interactions. This process effectively removes the muscle relaxant from the neuromuscular junction, allowing acetylcholine to resume normal function and restoring spontaneous muscle contraction almost immediately. Unlike traditional reversal agents such as neostigmine, which require cholinesterase inhibition and carry risks of bradycardia and increased secretions, Sugammadex offers a clean, predictable, and rapid onset of action without affecting other physiological systems. It is particularly valuable in emergency situations where immediate extubation is required or when residual paralysis poses a significant safety risk post-surgery.
Approved globally by major regulatory bodies including the FDA and EMA, Sugammadex has transformed anesthesia practice by enhancing patient safety and accelerating recovery times. It is administered intravenously in doses tailored to the depth of blockade, ranging from moderate to profound. Although generally well-tolerated, potential adverse reactions include hypersensitivity and rare cases of bradycardia. As a highly specific antidote, it represents a significant advancement in perioperative care, ensuring faster turnover in operating rooms and improved patient outcomes across diverse surgical specialties.